Biogen (BIIB) Q3 FY25 earnings call

Biogen delivered a strong quarter, driven by robust growth in its launch products which continue to offset the decline in the legacy MS portfolio. The company is strategically advancing its late-stage pipeline with high conviction, while also expanding its early-stage assets through disciplined business development. Efforts are focused on market creation for new therapies and optimizing the care pathway for Alzheimer's patients, positioning Biogen for sustainable long-term growth.